289 related articles for article (PubMed ID: 35707002)
41. Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.
Liao J; Ye Y; Xu X
Clin Transl Oncol; 2022 Oct; 24(10):1986-1997. PubMed ID: 35732871
[TBL] [Abstract][Full Text] [Related]
42. PDLIM2 acts as a cancer suppressor gene in non-small cell lung cancer via the down regulation of NF-κB signaling.
Shi H; Ji Y; Li W; Zhong Y; Ming Z
Mol Cell Probes; 2020 Oct; 53():101628. PubMed ID: 32621848
[TBL] [Abstract][Full Text] [Related]
43. Computer classification and construction of a novel prognostic signature based on moonlighting genes in prostate cancer.
Mei W; Jin L; Zhang B; Sun X; Yang G; Li S; Ye L
Front Oncol; 2022; 12():982267. PubMed ID: 36276080
[TBL] [Abstract][Full Text] [Related]
44. The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD).
Xin S; Sun X; Jin L; Li W; Liu X; Zhou L; Ye L
Front Genet; 2022; 13():877278. PubMed ID: 35706452
[TBL] [Abstract][Full Text] [Related]
45. Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes.
Zheng J; Dong H; Zhang T; Ning J; Xu Y; Cai C
Front Genet; 2022; 13():865052. PubMed ID: 35559024
[No Abstract] [Full Text] [Related]
46. Expression of the prognostic marker IL-8 correlates with the immune signature and epithelial-mesenchymal transition in breast cancer.
Liao H; Li H; Song J; Chen H; Si H; Dong J; Wang J; Bai X
J Clin Lab Anal; 2023 Feb; 37(3):e24797. PubMed ID: 36725216
[TBL] [Abstract][Full Text] [Related]
47. LTF Regulates the Immune Microenvironment of Prostate Cancer Through JAK/STAT3 Pathway.
Zhao Q; Cheng Y; Xiong Y
Front Oncol; 2021; 11():692117. PubMed ID: 34868909
[TBL] [Abstract][Full Text] [Related]
48. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
Mahmoudian RA; Mozhgani S; Abbaszadegan MR; Mokhlessi L; Montazer M; Gholamin M
J Mol Histol; 2021 Jun; 52(3):597-609. PubMed ID: 33884540
[TBL] [Abstract][Full Text] [Related]
49. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
50. Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance.
Sun F; Li L; Yan P; Zhou J; Shapiro SD; Xiao G; Qu Z
Nat Commun; 2019 Nov; 10(1):5324. PubMed ID: 31757943
[TBL] [Abstract][Full Text] [Related]
51. MiR-182 Is Upregulated in Prostate Cancer and Contributes to Tumor Progression by Targeting MITF.
Stafford MYC; McKenna DJ
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768146
[TBL] [Abstract][Full Text] [Related]
52. Identification of a Novel Epithelial-Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC.
Xin W; Zhao C; Jiang L; Pei D; Zhao L; Zhang C
Pathol Oncol Res; 2021; 27():585192. PubMed ID: 34257533
[TBL] [Abstract][Full Text] [Related]
53. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
54. Antioxidative stress protein SRXN1 can be used as a radiotherapy prognostic marker for prostate cancer.
Wang X; Yu J; Wen H; Yan J; Peng K; Zhou H
BMC Urol; 2023 Sep; 23(1):148. PubMed ID: 37726767
[TBL] [Abstract][Full Text] [Related]
55. The transcriptome signature analysis of the epithelial-mesenchymal transition and immune cell infiltration in colon adenocarcinoma.
Heryanto YD; Imoto S
Sci Rep; 2023 Oct; 13(1):18383. PubMed ID: 37884639
[TBL] [Abstract][Full Text] [Related]
56. Kruppel like factor 10 up-regulates PDZ and LIM domain containing protein 2 via nuclear factor kappa-B pathway to inhibit proliferation and inflammatory of fibroblastoid synovial cell in rheumatoid arthritis.
Wang S; Zha X; Ruan S; Yao S; Zhang X
Bioengineered; 2022 Jan; 13(1):1779-1790. PubMed ID: 34713769
[TBL] [Abstract][Full Text] [Related]
57. High expression of vinculin predicts poor prognosis and distant metastasis and associates with influencing tumor-associated NK cell infiltration and epithelial-mesenchymal transition in gastric cancer.
Li H; Wang C; Lan L; Behrens A; Tomaschko M; Ruiz J; Su Q; Zhao G; Yuan C; Xiao X; Li B; Yan L; Wu W; Li W; Chen J; He Y; Zhang C
Aging (Albany NY); 2021 Feb; 13(4):5197-5225. PubMed ID: 33535187
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.
Zhao L; Yu C; Zhou S; Lau WB; Lau B; Luo Z; Lin Q; Yang H; Xuan Y; Yi T; Zhao X; Wei Y
Oncotarget; 2016 Jan; 7(2):1408-20. PubMed ID: 26593252
[TBL] [Abstract][Full Text] [Related]
59. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.
Paniagua-Herranz L; Moreno I; Nieto-Jiménez C; Garcia-Lorenzo E; Díaz-Tejeiro C; Sanvicente A; Doger B; Pedregal M; Ramón J; Bartolomé J; Manzano A; Gyorffy B; Gutierrez-Uzquiza Á; Pérez Segura P; Calvo E; Moreno V; Ocana A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396898
[TBL] [Abstract][Full Text] [Related]
60. A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.
Ye C; Qin S; Qiu S; Zhao L; Miao J; Chen Y; Zhou T
Transl Androl Urol; 2022 Dec; 11(12):1691-1705. PubMed ID: 36632155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
